Extremely low doses of lepirudin in a patient with heparin-induced thrombocytopenia, high bleeding risk and renal insufficiency: Correspondence

British Journal of Haematology

Volumn 146, Issue 4, 2009, Pages 456-457

  Tardy Poncet, Brigitte ^a,b   Charier, David ^a   Diconne, Eric ^a   Zeni, Fabrice ^a   Garraud, Olivier ^a   Tardy, Bernard ^a   Campos, Lydia ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

Author keywords

Anticoagulation; Heparin induced thrombocytopenia; Thrombosis

Indexed keywords

ACENOCOUMAROL; DANAPAROID; HEPARIN; LEPIRUDIN;

ADULT; ANTICOAGULANT THERAPY; BLEEDING; CASE REPORT; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; LETTER; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; THROMBOSIS PREVENTION;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; CEREBRAL HEMORRHAGE; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HEPARIN; HIRUDINS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RENAL INSUFFICIENCY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 67749106289     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07764.x     Document Type: Letter

References (7)

1. Lewis, B.E., Wallis, D.E., Berkowitz, S.D., Matthai, W.H., Fareed, J., Walenga, J.M., Bartholomew, J., Sham, R., Lerner, R.G., Zeigler, Z.R., Rustagi, P.K., Jang, I.-K., Rifkin, S.D., Moran, J., Hursting, M.J. Kelton, J.G. for the ARG-911 Study Investigators (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation, 103, 1838 1843.
2. Lubenow, N., Eichler, P., Lietz, T. Greinacher, A. for the HIT investigators group (2005) Lepirudin in patients with heparin-induced thrombocytopenia: results of the third prospective (HAT 3) and a combined analysis of HAT-1, HAT -2 and HAT 3. Journal of Thrombosis and Haemostasis, 3, 2428 2436.
3. Magnani, H.N. (1997) Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia. Platelets, 8, 74 81.
4. Tardy, B., Lecompte, T., Boehlen, F., Tardy-Poncet, B., Elalamy, I., Morange, P., Gruel, Y., Wolf, M., François, D., Racadot, E., Camarasa, P., Blouch, M.T., Nguyen, F., Doubine, S., Dutrillaux, F., Alhenc-Gelas, M., Martin-Toutain, I., Bauters, A., Ffrench, P., de Maistre, E., Grunebaul, L., Mouton, C., Huisse, M.G., Gouault-Heilmann, M. Lucke, V. GEHT-HIT study group 2006) Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood, 108, 1492 1496.
5. Tardy-Poncet, B., Tardy, B., Reynaud, J., Mahul, P., Mismetti, P., Mazet, E. Guyotat, D. (1999) Efficacy and safety of danaparoid sodium (Org 10172) in critical ill patients with heparin associated thrombocytopenia. Chest, 115, 1616 1620.
6. Walenga, J.M., Hoppensteadt, D., Koza, M., Wallock, M., Pifarre, R. Fareed, J. (1991) Laboratory assays for the evaluation of recombinant hirudin. Haemostasis, 21, 49 63.
7. Warkentin, T.E. Greinacher, A. (2004) Heparin Induced Thrombocytopenia, 3rd edn. Marcel Dekker, New York.